Eric von Hofe

DecImmune Therapeutics (United States) — United States

Immunology and Microbiology · Life Sciences

22h-index1.8kcitations85works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(39), CAR-T cell therapy research(21), vaccines and immunoinformatics approaches(19), Monoclonal and Polyclonal Antibodies Research(16), Cancer Immunotherapy and Biomarkers(11)

Publications85 total

Target selection and clinical chimeric antigen receptor T cell activity against solid tumors
iLABMED·2023· 5 citedOpen Access
Inducible expression of interleukin-12 augments the efficacy of affinity-tuned chimeric antigen receptors in murine solid tumor models
Nature Communications·2023· 26 citedOpen Access
Data from Bispecific CAR T Cells against EpCAM and Inducible ICAM-1 Overcome Antigen Heterogeneity and Generate Superior Antitumor Responses
2023Open Access
Supplementary Figures from Bispecific CAR T Cells against EpCAM and Inducible ICAM-1 Overcome Antigen Heterogeneity and Generate Superior Antitumor Responses
2023Open Access
Supplementary Figures from Bispecific CAR T Cells against EpCAM and Inducible ICAM-1 Overcome Antigen Heterogeneity and Generate Superior Antitumor Responses
2023Open Access
Data from Bispecific CAR T Cells against EpCAM and Inducible ICAM-1 Overcome Antigen Heterogeneity and Generate Superior Antitumor Responses
2023Open Access
Abstract 5579: First-in-human study of ICAM-1-specific affinity tuned CAR T cells against advanced thyroid cancer
Cancer Research·2022
Abstract 5568: Revitalization of affinity-tuned CAR T cells via antigen-dependent release of interleukin-12
Cancer Research·2022
Abstract 558: Focused IL-12 cytokine delivery enhances function of affinity-tuned and real-time tracked ICAM-1-specific CAR T cells in solid tumors
Cancer Research·2022
Phase I study of AIC100 in relapsed and/or refractory advanced thyroid cancer and anaplastic thyroid cancer.
Journal of Clinical Oncology·2022· 6 cited
121 ICAM-1-specific affinity tuned CAR T cells expressing SSTR2 for real-time imaging
Regular and Young Investigator Award Abstracts·2021Open Access
Bispecific CAR T Cells against EpCAM and Inducible ICAM-1 Overcome Antigen Heterogeneity and Generate Superior Antitumor Responses
Cancer Immunology Research·2021· 55 citedOpen Access
Abstract LB-381: Mitigating on-target off-tumor cytotoxicity of EpCAM CAR-T by affinity tuning
Cancer Research·2020
Abstract 6598: Eradication of EpCAM expressing solid tumors by low-affinity CAR T cells
Cancer Research·2020· 4 cited
Abstract 6597: Highly localized, inducible interleukin-12 release augments ICAM-1 CAR T cell activity against solid tumors
Cancer Research·2020
Publisher Correction: Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy
Scientific Reports·2020Open Access
Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy
Scientific Reports·2019· 77 citedOpen Access
Abstract 2329: Clinical manufacturing of CAR T cells targeting ICAM-1 for a phase I study against advanced thyroid cancer therapy
Cancer Research·2019
Abstract 2329: Clinical manufacturing of CAR T cells targeting ICAM-1 for a phase I study against advanced thyroid cancer therapy
Immunology·2019
Subgroup efficacy evaluation of the AE37 HER2 vaccine in breast cancer patients in the adjuvant setting.
Journal of Clinical Oncology·2017· 12 cited
page 1 of 5Next →

Frequent Co-authors

Minzhen Xu(11), Nikoletta L. Kallinteris(9), Robert E. Humphreys(9), Paul Kleihues(7), George E. Peoples(6), Sonia A. Perez(6), Michael Papamichail(6), Xueqing Lu(6), Elizabeth A. Mittendorf(5), Constantin N. Baxevanis(5), Moonsoo M. Jin(5), James L. Murray(4), Sathibalan Ponniah(4), Yanping Yang(4), Laurence Van Overtvelt(3), Erik Wambre(3), Bernard Maillère(3), Didier G. Ebo(3), Philippe Moingeon(3), Alexandros Ardavanis(3)